» Articles » PMID: 20381496

Quantification of Circulating Endothelial Progenitor Cells in Human Peripheral Blood: Establishing a Reliable Flow Cytometry Protocol

Overview
Publisher Elsevier
Date 2010 Apr 13
PMID 20381496
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Accurate enumeration of circulating endothelial progenitor cells (CEP) is essential for their potential application as biomarkers of angiogenesis. In this study different stem cell markers (CD34, CD133) and endothelial cell antigens (KDR/VEGFR-2, CD31) in different flow cytometric protocols were assessed for the purpose of CEP quantification.

Methods: Blood samples from 19 healthy volunteers and 16 patients with different cancer types were analyzed by means of flow cytometry. Mononuclear cell gating was compared to additional gating on CD45-negative cells. CD34+/KDR+ and CD31+/CD133+ cells were analyzed in a direct immunolabeling approach. CEP were measured at different time points in individual patients and after storage of blood samples for 24h and 48h, respectively.

Results: In contrast to previous studies, measurement of CD34+/KDR+ cells was an unreliable method for CEP enumeration, regardless of the applied gating strategy. However, detection of CD31+/CD133+ cells in a combined mononuclear cell and CD45-negative gating approach provided a reproducible method for CEP quantification. In individual blood donors, the CEP numbers were stable over time. For the first time, it was demonstrated that CEP are unstable in extracorporeal blood samples.

Conclusion: In this study, a reproducible protocol for CEP quantification was established. This protocol should facilitate future studies with the goal to further define the role of CEP as angiogenic biomarkers.

Citing Articles

Endothelial progenitor cells as an angiogenic biomarker for the diagnosis and prognosis of lung cancer.

Najjar F, Alsabe H, Sabbagh H, Al-Massarani G, Aljapawe A, Alamalla N Rep Pract Oncol Radiother. 2025; 29(5):544-557.

PMID: 39759554 PMC: 11698562. DOI: 10.5603/rpor.102618.


Extracellular vesicles engineering by silicates-activated endothelial progenitor cells for myocardial infarction treatment in male mice.

Yu B, Li H, Zhang Z, Chen P, Wang L, Fan X Nat Commun. 2023; 14(1):2094.

PMID: 37055411 PMC: 10102163. DOI: 10.1038/s41467-023-37832-y.


Angiogenic stem cell delivery platform to augment post-infarction neovasculature and reverse ventricular remodeling.

Shin H, Thakore A, Tada Y, Pedroza A, Ikeda G, Chen I Sci Rep. 2022; 12(1):17605.

PMID: 36266453 PMC: 9584918. DOI: 10.1038/s41598-022-21510-y.


Pathological Roles for Endothelial Colony-Forming Cells in Neonatal and Adult Lung Disease.

Robertson J, Erzurum S, Asosingh K Am J Respir Cell Mol Biol. 2022; 68(1):13-22.

PMID: 36215049 PMC: 9817912. DOI: 10.1165/rcmb.2022-0318PS.


Protocol for the Stimulating β-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral....

Bubb K, Harmer J, Finemore M, Aitken S, Ali Z, Billot L BMJ Open. 2021; 11(9):e049858.

PMID: 34588252 PMC: 8479946. DOI: 10.1136/bmjopen-2021-049858.